Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Dermatologic 1

Conditions

Uveal Melanoma 1Ovarian Neoplasms 1Melanoma 1Carcinoma, Hepatocellular 1

Interventions

Ipilimumab 10Nivolumab 9Interleukin-2 5Cyclophosphamide 5pembrolizumab 3incomplete Freund's adjuvant 3fludarabine phosphate 3Radiosurgery 3Melphalan 3ADI PEG20 3sotrastaurin 2fludarabine 2Specimen Handling 2Ranibizumab 2Magnetic Resonance Spectroscopy 2MART-1 Antigen 2CTLA-4 Antigen 2Biopsy 2utomilumab 1tocilizumab 1siremadlin 1sargramostim 1ruxolitinib 1relatlimab 1pentetreotide 1obinutuzumab 1montanide ISA 51 1lifileucel 1gp100 Melanoma Antigen 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Uveal Melanoma × Polyethylene Glycols × Clear all
NCT01665183 2016-02-25

Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma

Polaris Group

Phase 1 Completed
8 enrolled
DermatologicGynecologic

Uveal Melanoma, Melanoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡